<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-73014</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Evaluation of cardiovascular risk in the longitudinal phase of the Mediterranean study</dc:title>
<dc:description xml:lang="en">Introduction and objectives. There is little information on cardiovascular longitudinal studies. In Spanish patients with hypertension (AHT)) and/or hypercholesterolemia (HC), with poor initial control of blood pressure (BP) and/or total cholesterol (TC), incidencerate (IR), cumulative incidence (CI), relative risks (RR), survival curves (SC), therapeutic compliance (TC) were quantifi ed and the Framingham-Anderson scale (FAS) was adjusted to our patients. Patients and Methods. A total of 6,893 primary prevention patients with AHT and/or with HC were included in primary prevention, with an average of 1.22 years of follow-up. A total of 480 physicians participated. Incidence rate (IR), cumulative incidence (CIN), relative risks (RR), survival curves (SC) by Kaplan-Meier method, and therapeutic compliance (TCOM) by Haynes-Sackett self-reported questionnaire were calculated. The Framingham-Anderson scale (FAS) was validated with Pearson&#146;s correlation coeffi cient (r)and intraclass correlation index (ICI).Results. CIN was 1.59% (1.31-1.90); the IR 1,321.6 cardiovascular events/ 100,000 patients/year (1,026.6-1,598.8). RRs with statistical signifi cance were: age (p = 0.03). Blood pressure at the end of the study (p = 0.02), coronary background (p = 0.00), left ventricular hypertrophy (LVH) (p = 0.00), microalbuminuria (p = 0.02), CT &amp;#8805; 250 mg/dl (p = 0.01), fasting glycemia (Gb) &amp;#8805; 126 mg/dl (p = 0.00), creatinine &amp;#8805; 1.2 mg/dl at thebeginning (p = 0.00) and at the end of the study (p = 0.00), and poor compliance in HC patients (p = 0.00). SC have statistical signifi cance (p &lt; 0.05) for AHT background, fastingglucose &amp;#8805; 126 mg/dl, target organ damage, and high cardiovascular risk with FAS scale. The adjusted FAS formula for global cardiovascular risk was (0.415 x FAS Risk%) + 0.517%,r = 0.9962 (p = 0.00) and ICI = 0.9969 (p &lt; 0.0001)...(AU)</dc:description>
<dc:creator>Abellán-Alemán, J</dc:creator>
<dc:creator>Sánchez-Ruiz, T</dc:creator>
<dc:creator>Gil-Guillén, V. F</dc:creator>
<dc:creator>Orozco-Beltrán, D</dc:creator>
<dc:creator>Aznar-Vicente, J</dc:creator>
<dc:creator>Llisterri-Caro, J. L</dc:creator>
<dc:creator>Pascual Pérez, M</dc:creator>
<dc:creator>Merino-Sánchez, J</dc:creator>
<dc:creator>Márquez Contreras, E</dc:creator>
<dc:creator>Amorós-Barber, T</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos. Es escasa la información de estudios cardiovasculares longitudinales.En hipertensos (HTA) y/o hipercolesterolémicos (HCL) españoles, con mal controlinicial de la presión arterial (PA) y/o del colesterol total (CT) se cuantifi ca la tasa deincidencia (TI), la incidencia acumulada (IA), los riesgos relativos (RR), las curvas de supervivencia(CS), el cumplimiento terapéutico (CU) y se ajusta la escala de Framingham-Anderson (FA) a nuestro entorno.Pacientes y métodos. Se analizaron 6.893 HTA y/o HCL en prevención primaria que aportaronun promedio de 1,22 años de seguimiento. Participaron 480 médicos. Se calcularon:la TI, IA y los RR; el método de Kaplan-Meier para la CS; Haynes-Sackett adaptado parael CU; el ajuste de FA por la recta de los mínimos cuadrados, coefi ciente de correlaciónde Pearson (r) e intraclase (cci).Resultados. La IA fue 1,59% (1,31-1,90); la TI de 1.321, 6 eventos cardiovasculares por100.000 pacientes/año (1.026,6-1.598,8). Los RR signifi cativos fueron: edad (p = 0,03),PA fi nal (p = 0,02), antecedentes coronarios (p = 0,00), hipertrofi a ventricular izquierda(HVI) (p = 0,00), microalbuminuria (p = 0,02), CT &amp;#8805; 250 mg/dl al inicio (p = 0,01), glucemiabasal (Gb) &amp;#8805; 126 mg/dl al inicio (p = 0,00), creatinina &amp;#8805; 1,2 mg/dl al inicio (p = 0,00) y fi nal (p =0,00), y no CU en HCL (p = 0,00). Las CS realizadas por antecedentes de HTAy/o HCL, existencia o no de Gb &amp;#8805; 126 mg/dl, existencia o no de lesión de órganos diana,y tener o no riesgo cardiovascular (RCV) alto con FA, fueron signifi cativas (p &lt; 0,05). Elajuste del FA para RCV global fue: (0,415 x Riesgo FA%) + 0,517%, obtuvo una r = 0,9962(p = 0,00) y un cci = 0,9969 (p &lt; 0,0001).Conclusiones. Se ajustó la ecuación FA en nuestros pacientes, con datos propios. Se cuantificaron los factores pronósticos y CS. Se cuantifi có un benefi cio entre CU y disminuciónde RCV en HCL(AU)</dc:description>
<dc:source>Rev Clin Esp;209(3): 118-130, mar.2009. tab, ilus</dc:source>
<dc:identifier>ibc-73014</dc:identifier>
<dc:title xml:lang="es">Valoración del riesgo cardiovascular en la fase longitudinal del estudio Mediterránea</dc:title>
<dc:subject>^d7152^s22080</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d7117^s22080</dc:subject>
<dc:subject>^d28604</dc:subject>
<dc:subject>^d2359^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28630</dc:subject>
<dc:subject>^d8688^s22080</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d7152^s22057</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d7117^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200903</dc:date>
</metadata>
</record>
</ibecs-document>
